Service

Regenerative Medicine

Our Regenerative Medicine team was formed in December, 2015. With consultation services for both business and developmental planning, and an operational division for implementation, the Regenerative Medicine team can provide guidance in developing an optimal solution.

Remedy Group's Features of Regenerative Medicine

  • Highly Specialized Team with Extensive Experience

    We are now capable of overseeing all areas available for development

    Regenerative Medicine Specified by Government Order
    Partial Revision of Order for Enforcement of Pharmaceutical Affairs Law, appended Table 1 (Re Article 2)

    Human Cell/Tissue Products

    • Human Somatic Cell Therapy Product
    • Human Somatic Stem Cell Therapy Product
    • Human Embryonic Stem Cell Therapy Product
    • Human Artificial Pluripotent Stem Cell Therapy Product

    Animal Cell/Tissue Products

    • Animal Somatic Cell Therapy Product
    • Animal Somatic Stem Cell Therapy Product
    • Animal Embryonic Stem Cell Therapy Product
    • Animal Artificial Pluripotent Stem Cell Therapy Product

    Gene Therapy Products

    • Plasmid Vector Product
    • Virus Vector Product
    • Gene Expression Therapy Product(Excluding those listed in preceding 2 items)

    Performance Profile

    Human Cell/Tissue Products 38%, Human Somatic Stem Cell Therapy Product 23%, Virus Vector Product 31%, Human Artificial Pluripotent Stem Cell Therapy Product 8% Human Cell/Tissue Products 38%, Human Somatic Stem Cell Therapy Product 23%, Virus Vector Product 31%, Human Artificial Pluripotent Stem Cell Therapy Product 8%
  • Support to Rapidly Changing Regulations

    The major difficulties of developing Regenerative Medicines are that regulations and evaluation methods have not yet caught up to the advancements in the technologies.
    Remedy, is able to provide support to academia, healthcare institutions, and industry, through experience and accumulated data.

    Support Achievements

    Audit 3, Pharmacovigilance 1, Data and safety Monitoring Board 1, Medical Writing 4, Statistic Analysis 6, Data Management 5, Quality Assurance 4, Monitoring 6, Consultation 7 Audit 3, Pharmacovigilance 1, Data and safety Monitoring Board 1, Medical Writing 4, Statistic Analysis 6, Data Management 5, Quality Assurance 4, Monitoring 6, Consultation 7

    *Contents Of Consultation

    • Consultation on Clinical Evaluation of small case of a few cases
    • Support for implementing system of Clinical Trial (Creation of SOP Document, etc.)
    • Development Strategy Planning Support (Exit Strategy)
    • Clinical Trial Planning Support
    • Consultation Support for PMDA/Various Authorities
    • Response Support for Cartagena Act
    • Support for Implementing Clinical Trial Operation in response to Cartagena Act
  • Fore-Sighted Market Valuation of Investment Value

    We have formed a specialized team in the Regenerative Medicine business, capable of determining present investment value (NET Present Value: NPV) of projects based on various data. With thorough market valuation, we are capable of developing an effective strategy that provides an accurate investment value for our clients.

    Points

    • As a member of the Forum for Innovative Regenerative Medicine (FIRM), we are actively contributing to the advancement to Regenerative Medicine products
    • We are focused in developing specialists that will lead the industry, through the implementation of a training program

    Starting From Strategy Development to Clinical Use

    As Experts in the field of Regenerative Medicine,
    We will propose the most optimal pathway to an Exit Strategy Starting From Strategy Development to Clinical Use

Regenerative Medicine Column Latest Articles